

Remarks

I. Support for Amendments

The foregoing amendments to the specification have been made to update the priority information at page 1 of the specification, to delete text at page 2 of the specification, and to provide proper format for the trademarks used in the application at pages 70 and 77 in accordance with MPEP § 608.01(v).

Support for the foregoing amendments to the claims may be found throughout the specification. Specifically, support for new claim 52 may be found, *inter alia*, at page 10, lines 12-16, at pages 31-33, and throughout the Examples; support for new claims 53 and 54 may be found, *inter alia*, at page 15, lines 24-26; support for new claims 55 and 56 may be found, *inter alia*, at pages 12 and 16, and in claims 44 and 45 as originally filed; support for new claim 57 may be found at page 12, lines 18-21, at page 15, lines 28-29, at page 16, lines 12-15, and at page 29, lines 5-26; support for new claims 58-59 may be found at page 43, lines 24-25 and throughout the Examples, particularly in Examples 1-3 at pages 51-61; support for new claim 60 may be found at pages 31-33, in Figure 1, and throughout the Examples; support for new claim 61 may be found at pages 41-46; support for new claims 62-63 may be found at pages 23, 31, 33 and 36-37, and in Examples 1-3 at pages 51-61; support for new claims 64-65 may be found at pages 36-41; support for new claim 66 may be found at pages 31-33 and in Figures 1 and 2; and support for new claims 67-68 may be found at pages 10-11, 15-16, 22 and 29-30.

Accordingly, the present amendments to the specification and claims do not add new matter, and their entry is respectfully requested.

II. Status of the Claims

By the foregoing amendments, claims 2-51 have been cancelled without prejudice or disclaimer, and new claims 52-68 are sought to be added. These amendments do not introduce new matter into the application. Upon entry of the foregoing amendments, claims 1 and 52-68 are pending in the present application, with claims 1 and 52 being the independent claims.

III. Conclusion

It is respectfully believed that the present application is in condition for immediate examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt entry and favorable consideration of this preliminary amendment are earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: May 16, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600
P103-42.wpd

00885797-051601
T09750-625880

Version with markings to show changes made

In the Specification:

In the specification at page 1, the paragraph appearing at lines 4-11 (the Cross-Reference section) is sought to be amended as follows:

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. Application No. 09/296,281, filed April 22, 1999, which is a divisional of U.S. Application No. 09/177,387, filed October 23, 1998, which claims the benefit of the filing date of U.S. Provisional Application No. 60/065,930, filed October 24, 1997, [the disclosure of which is incorporated by reference herein in its entirety. The present application is also related to U.S. Application No. 08/663,002, filed June 7, 1996, and to U.S. Application No. 08/486,139, filed June 7, 1995,] the disclosures of which applications are incorporated by reference herein in their entireties.

In the specification at page 2, the paragraph appearing at lines 16-18 is sought to be deleted.

In the specification at page 70, the partial paragraph appearing at lines 36-41 is sought to be amended as follows:

Part V: Expression of Fusion Proteins

Two colonies from each transformation were picked into 2 ml of rich medium [(CircleGrow) (CIRCLEGROW® brand culture medium, Bio101 Inc.) in 17 × 100 mm plastic tubes [Falcon 2059] (FALCON® brand plasticware, Cat. No. 2059, Becton Dickinson) containing 100 µg/ml ampicillin and shaken vigorously for about 4 hours at 37°C, at which time the cultures were visibly turbid. One ml of each culture was transferred to a new tube containing 10 µl of 10% (w/v) IPTG

In the specification at page 77, the paragraph appearing at lines 7-17 is sought to be amended as follows:

Twelve of the 26 small colonies were grown overnight in rich broth [(CircleGrow) (CIRCLEGROW® brand culture medium)] that contained 25 µg/ml kanamycin, and miniprep DNAs were prepared from these cultures. All twelve miniprep plasmids were about 8 kb in size, which corresponded to the size expected for replacement of the chloramphenicol resistance and tet repressor genes in pEZC1202 with the 5.2 kb PCR product. The predicted recombinant product is shown in Figure 9C. Two of these plasmids were cut with *Ava*I (8 sites predicted) and *Bam*HI (4 sites predicted). All the predicted *Ava*I fragments appeared to be present. One of the *Bam*HI sites predicted in the PCR product (the one closest to the attB end) was absent from both minipreps, but the other *Bam*HI fragments were consistent with the expected structure of the cloned 5.2 kb PCR product.

In the Claims:

The claims are sought to be amended as follows:

Claims 2-51 are sought to be cancelled, without prejudice or disclaimer.

New claims 52-68 are sought to be entered.

09/296,281 - 09/296,281